Lessons Learned: New FDA Guidance On Meetings With Sponsors Adds Depth
This article was originally published in Pharmaceutical Approvals Monthly
FDA's new iteration of its guidance on meetings with sponsors reflects lessons learned during the surge in meeting requests the agency has had in the nine years since FDA issued the original formal meetings final guidance in February 2000
You may also be interested in...
As FDA rolls out its Good Review Management Principles - its attempt to improve FDA's timely review of drug applications through professional best practices - the agency is stressing the importance of sponsors submitting complete applications to facilitate this process
An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.